Key Stats for Johnson & Johnson Stock
- Current Price: $235
- Target Price: $301
- Street Target: $241.08
- Long-Term Annualized IRR: 16.61%
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Johnson & Johnson (JNJ) is navigating the “final stretch” of a decade-long journey to bring its next-generation robotic surgical platform to market.
Speaking at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, Hani Abouhalka, Group Chairman of Surgery, detailed a vision that anchors J&J’s future in its 140-year surgical legacy.
The narrative has shifted: J&J is no longer just a pharmaceutical powerhouse, but a company entering a “defining moment” for MedTech innovation.
The centerpiece of this transformation is Ottava, J&J’s soft-tissue robotic system.
Unlike existing competitors that rely on bulky external carts, Ottava features arms that are integrated directly into the surgical table.
These arms can be stored invisibly when not in use, effectively making the table the robot itself.
This design directly addresses a critical hospital bottleneck: the need for dedicated, single-purpose robotic operating rooms (ORs) that sit idle if a robotic case is canceled.
“We believe that ORs should be ORs to serve all surgery, whether it’s open, lab, or robotics,” Abouhalka stated, noting that Ottava’s architecture also allows surgeons to natively use gravity for organ manipulation, a technique comfortable for laparoscopic surgeons but traditionally difficult in robotics.
To ground this timeline in reality, J&J officially secured an Investigational Device Exemption (IDE) from the FDA to proceed with clinical trials, specifically targeting high-volume procedures like inguinal hernia and submitting an umbrella indication for upper gastrointestinal surgeries.
Beyond hardware, J&J is rolling out Polyphonic, an open digital ecosystem designed to unify surgical data.
Currently, 97% of surgeons report they do not have the right data at the right time.
Polyphonic aims to bridge this gap by structuring surgical videos to reduce the 25% complication rate currently seen in global surgeries.
Simultaneously, J&J is expanding its Monarch robotic platform, executing a highly anticipated launch in urology to become the industry’s first robotic endoluminal (internal channel) and percutaneous (through-skin) access solution for kidney stone removal.
See historical and forward estimates for Johnson & Johnson stock (It’s free!) >>>
Is Johnson & Johnson Undervalued Today?
While J&J is often valued by the Street as a defensive pharmaceutical play, the market’s recent 11.75% drawdown in May 2025 has created a dislocation as the company pivots toward higher-margin MedTech recurring revenue.
Evaluated on standalone valuation data from TIKR, JNJ currently trades at an NTM EV/EBITDA multiple of 16.10x and an NTM P/E of 20.79x.
For diversified healthcare leaders, Enterprise Value-to-EBITDA is the preferred metric because it captures the massive cash generation of the surgical business while smoothing out the capital-heavy nature of pharmaceutical research and development.
When stacked against the core peer group provided in the TIKR data, J&J commands a premium over legacy pharmaceutical giants but remains highly attractive relative to pure-play surgical innovators.
Pfizer Inc. (PFE) trades at a deep discount of 8.17x EV/EBITDA, while Roche Holding AG trades at 10.72x and Novartis AG sits at 13.28x. J&J’s higher 16.10x multiple is fully justified by its superior margin profile and its unique ability to drive “attachment.”
For example, management is integrating the Ethicon 4000 series, their most secure surgical staple line, as an exclusive offering on the Ottava platform, ensuring that surgeons who rely on J&J’s instruments are directly incentivized to adopt J&J’s robots.
With the Current Price of $235.37 sitting below the $241.08 Street Target and significantly below the robust internal model target, the risk-reward profile appears heavily tilted toward the upside.
Analyze historical valuation multiples for JNJ against its peers (It’s free!) >>>
The TIKR Model Analysis
The TIKR Advanced Model calculates the compounding financial impact of J&J successfully monetizing the Ottava rollout and its digital surgical backlog.
- Current Price: $235
- Target Price: $301
- Potential Total Return: +27.9%
- Long-Term IRR: 16.6%
Build a 4-year Valuation Model for JNJ for yourself (It’s free) >>>
The Mid Case model projects an aggressive $301.04 target price, fueled by a robust 5.9% Revenue CAGR over the forecast period. This growth assumes that the “final stretch” of robotic placements and the expansion into urology will successfully offset the mature growth rates of legacy pharmaceutical categories.
The primary engine of this valuation is the defense of Net Income Margins, which are modeled at a highly profitable 30.9% in the Mid Case. Achieving this requires management to successfully transition surgical teams from manual laparoscopy to connected robotic platforms, where J&J can capture higher lifetime value through proprietary software (Polyphonic) and instruments. If J&J executes this “table-integrated” strategy effectively, the 16.61% long-term IRR presents a highly compelling anchor for a healthcare portfolio.
Conclusion: Johnson & Johnson is no longer just a defensive pharmaceutical conglomerate; it is actively reclaiming its surgical legacy through a massive MedTech transformation. While the market digested an 11.75% drawdown in 2025, the underlying fundamentals, the launch of the table-integrated Ottava system, the expansion of the Monarch platform into urology, and a clear path to 30.9% net margins, point to a significant value unlock. Trading at a highly reasonable 16.10x EV/EBITDA multiple compared to pure-play surgical peers, the path to the $301.04 TIKR model target presents a highly compelling opportunity for investors willing to bet on the final stretch of J&J’s robotic journey.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Johnson & Johnson?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Johnson & Johnson, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Johnson & Johnson alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Johnson & Johnson on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
